Internal Medicine · Bronx, NY
NPI
1942381405
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
3
Medicare group memberships
Hospitals
0
Hospital affiliations
1225 Gerard Ave
Bronx, NY, 10452
Phone (718) 960-2800
Groups this clinician bills Medicare through
Medicare paid, 2024
$2,297
219 services
Medicare patients, 2024
25
Average age 69
Drug cost, 2024
$6.7M
29,896 prescriptions
Company payments, 2025
$4,762
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Fernando S Mora-McLaughlin was code 80048 (clinical chemistry), 34 times for 23 patients. In total Fernando S Mora-McLaughlin billed 219 services in 16 codes, and Medicare paid $2,297.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-01-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 80048 Clinical Chemistry | Office | 34 | 23 | $8.29 | $282 |
| 80061 Clinical Chemistry | Office | 31 | 21 | $13.12 | $407 |
| 82043 Clinical Chemistry | Office | 30 | 20 | $5.66 | $170 |
| 84443 Clinical Chemistry | Office | 30 | 21 | $16.46 | $494 |
| 83036 Blood Count | Office | 24 | 15 | $9.52 | $228 |
| 86780 Immunoassay | Office | 24 | 19 | $12.98 | $312 |
| 81003 Clinical Chemistry | Office | 23 | 18 | $2.20 | $50.6 |
By year: 2022 $2,298 for 236 services; 2023 $2,247 for 227 services; 2024 $2,297 for 219 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 80048 Clinical Chemistry | 34 | 23 | $8.29 | $282 |
| 80061 Clinical Chemistry | 31 | 21 | $13.12 | $407 |
| 82043 Clinical Chemistry | 30 | 20 | $5.66 | $170 |
| 84443 Clinical Chemistry | 30 | 21 | $16.46 | $494 |
| 83036 Blood Count | 24 | 15 | $9.52 | $228 |
| 86780 Immunoassay | 24 | 19 | $12.98 | $312 |
| 81003 Clinical Chemistry | 23 | 18 | $2.20 | $50.6 |
Medicare prescription drug claims, 2024
In 2024, the drug Fernando S Mora-McLaughlin prescribed most often to Medicare patients was Atorvastatin Calcium, with 1,723 prescriptions and refills. In total Fernando S Mora-McLaughlin wrote 29,896 Medicare prescriptions that cost $6.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Atorvastatin Calcium Generic | 1,723 | 4,407 | 446 | $21K |
| Omeprazole Generic | 842 | 1,835 | 207 | $10K |
| Fluticasone Propionate Generic | 774 | 1,208 | 184 | $7,117 |
| Diclofenac Sodium Generic | 764 | 913 | 176 | $89K |
| Gabapentin Generic | 713 | 1,430 | 176 | $7,369 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 574 | 712 | 108 | $23K |
| Jardiance Empagliflozin | 574 | 926 | 113 | $524K |
| Amlodipine Besylate Generic | 548 | 1,398 | 142 | $3,111 |
| Ozempic Semaglutide | 542 | 752 | 95 | $679K |
| Metformin Hcl Generic | 477 | 1,140 | 122 | $2,467 |
| Alcohol Prep Pads Alcohol Antiseptic Pads | 475 | 633 | 105 | $5,391 |
| Famotidine Generic | 461 | 1,048 | 114 | $5,747 |
| Metoprolol Succinate Generic | 401 | 982 | 101 | $6,493 |
| Ammonium Lactate Generic | 393 | 463 | 73 | $7,545 |
| Linzess Linaclotide | 360 | 519 | 66 | $263K |
Brand drugs: 6,904 claims; generic drugs: 21,383 claims; opioid claims: 650.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Fernando S Mora-McLaughlin $4,762 ($4,762 in general payments such as food, travel and fees) from 18 companies. The largest payer was Intra-Sana Laboratories with $1,080.
| Company | Payments | Amount |
|---|---|---|
| Intra-Sana Laboratories | 15 | $1,080 |
| Xeris Pharmaceuticals, Inc. | 7 | $733 |
| Abbvie Inc. ABBV | 19 | $650 |
| Dexcom, Inc. DXCM | 12 | $461 |
| Novo Nordisk Inc NVO | 10 | $426 |
| Gilead Sciences, Inc. GILD | 13 | $332 |
| ViiV Healthcare Company GSK | 12 | $254 |
| Amgen Inc. AMGN | 5 | $218 |
| Axsome Therapeutics, Inc. AXSM | 4 | $181 |
| AstraZeneca Pharmaceuticals LP AZN | 6 | $136 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.